The European Patent Office will grant Insmed Incorporated EU Patent No. 1909759 for Arikace liposomal amikacin for inhalation, according to Insmed. The composition of matter patent, titled “Sustained release of anti-infective aminoglycosides,” covers formulations of aminoglycosides, including amikacin, with Insmed’s liposomal delivery platform, formulation methods, and use of the formulations for the treatment of pulmonary infections. The patent will provide exclusivity through July 19, 2026 at minimum.
Insmed is developing Arikace for the treatment of Pseudomonas aeruginosa infections in cystic fibrosis patients and for the treatment of nontuberculous mycobacteria (NTM) lung infections. In August 2012, the US Patent and Trademark Office (USPTO) issued a composition of matter patent for Arikace.
Insmed President and CEO Will Lewis said, “This patent allowance underscores the strength of our technology development team and recognizes the technology’s innovation. This expanded patent coverage supports our goal to tackle Pseudomonas aeruginosa in CF and NTM, conditions which are serious and often times fatal lung infections with limited current treatment options. Arikace, with its novel liposomal delivery of amikacin, offers the potential to provide these patients with a safe and effective, once-daily therapy. Together, we believe that the US and European patents will provide a strong foundation for our future commercial interests and global development of our liposomal amikacin for inhalation.”
Read the Insmed press release.
